MODERN POSSIBILITIES OF MEDICAL TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BLADDER CANCER


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Currently, possibilities of effective drug treatment of locally advanced and metastatic bladder cancer (mBIC) are rather limited. The main drug of 1st line is cisplatin, the use of which is difficult for half of the patients because of its nephrotoxicity. The question of choice of effective treatment after progression on the 1st line therapy is of particular importance. Currently vinflunine is the only drug with proven efficacy in mBlC patients after progression on cisplatin-containing chemotherapy regimens, and it is recommended for use in Europe and Russia. Characteristic safety profile of vinflunine allows to consider this drug in combination with gemcitabine as a worthy alternative to cisplatin-containing regimens in the 1st-line therapy in the future.

Texto integral

Acesso é fechado

Sobre autores

K. Vorontsova

FSBI "RORC n.a. N.N. Blokhin" of RMH

PhD, oncologist at the department of chemotherapy and combined therapy of malignant tumors Moscow

L. Zhukova

FSBI "RORC n.a. N.N. Blokhin" of RMH

Moscow

Bibliografia

  1. Von der Maase H., Hansen S.W., Roberts J.T., Dogiiotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000;18:3068-77.
  2. NCCN clinical practice guidelines. Bladder Cancer. V2 2015.
  3. Bellmunt J., Orsola A., Leow J.J., Wiegel T., De Santis M., Horwich A. on behalf of the ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014; 25(Suppl. 3):iii40-iii48.
  4. Sternberg C.N., de Mulder P.H., Schornagel J.H., Theodore C., Fossa S.D., van Oosterom A.T., Witjes F., Spina M., van Groeningen C.J., de Balincourt C., Collette L; European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 2001;19:2638-46.
  5. Sternberg C.N., de Mulder P., Schornagel J.H., Theodore C., Fossa S.D., van Oosterom A.T., Witjes J.A., Spina M., van Groeningen C.J., Dudos B, Roberts J.T., de Balincourt C., Collette L.; EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer. 2006;42:50-4.
  6. WitjesJ.A, Comperat E., Cowan N.C., De Santis M., GakisG,LebretT.,RibalM.J.,VanderHeijdenA.G, Sherif A.; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 2014;65(4):778-92.
  7. Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K., Dreicer R., Vogelzang N., Sternberg C., Bajorin D.F., Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211-14.
  8. De Santis M., Bellmunt J., Mead G., Kerst J.M., Leahy M., Maroto P., Gil T., Marreaud S., Daugaard G., Skoneczna I., Collette S., Lorent J., de Wit R., Sylvester R. Randomized phase II/ III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 2012;30:191-99.
  9. Javlor® European Public Assessment Report doc EMEA/CHMP/370293/2009.
  10. Sambert N., Delord J.P., Tourani J.M., Fumoleau P., Ravaud A., Pinel M.C., Petain A., Nguyen T., Nguyen L. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br. J. Clin. Pharmacol. 2014;77(3):498-508.
  11. De Santis M., Wiechno P.J., Bellmunt J., Lucas C., Su W.-C., Albiges L., Lin C.-C.,Senkus-Konefka E., Flechon A., Mourey L., Necchi A., Loidl W.C., Retz M.M., Vaissiere N., Culine S. Vinflunine - gemcitabine versus vinflunine - carboplatin as first-line chemotherapy in cisplatin-ufit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Annals of Oncology. 2016; 27:449-54.
  12. Rink M., Oechsle K., Seidel C., von Amsberg G., Bokemeyer C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond - A Comprehensive Review of the Current Literature. The J. of Urology. 2016;195:254-63.
  13. Kim Y.S., Choi M.K., Hong JY., Maeng C.H., Lee S., Hwang I.G., Lee S.-C., Sun J.-M., Park S.H., Lee J., Lim H.Y. A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma. J. Clin. Oncol. 2013;(Suppl. 31):abstract e15613.
  14. Joly F., Tchen N., Chevreau C., Henry-Amar M., Priou F., Chinet-Charrot P., Rolland F., Droz J.-P., Journet V., Culine S. Clinical benefit of second-line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. J. мам при невозможности применения последних больными местно-распространенным или мРМП в 1-й линии терапии. Clin. Oncol. 2004;(Suppl. 22):abstract 4619.
  15. Vaughn D.J., Broome C.M., Hussain M., Gutheil J.C., Markowitz A.B. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 2002;20:937.
  16. Ko Y.J., Canil C.M., Mukherjee S.D., Winquist E., Elser C., Eisen A., Reaume M.N., Zhang L., Sridhar S.S. Nano-particle albumin-bound pacli-taxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013; 14:769.
  17. Lee J.L., Ahn J.H., Park S.H., Lim H.Y., Kwon J.H., Ahn S., Song C., Hong J.H., Kim C.S., Ahn H. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs. 2012;30:1984.
  18. Akaza H., Naito S., Usami M., Miki T., Miyanaga N., Taniai H.; Japanese Gemcitabine Study Group. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience. Jpn. J. Clin. Oncol. 2007;37:201.
  19. Albers P., Siener R., Hartlein M., Fallahi M., Haeutle D., Perabo F.G., Steiner G., Blatter J., Müller S.C.; German TCC Study Group of the German Association of Urologic Oncology. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie. 2002;25:47.
  20. Gebbia V., Testa A., Borsellino N., Mauceri G., Varvara F., Tirrito M.L., Sambataro D., Fallica G.: Single agent 2'2-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin. Ter. 1999;150:11.
  21. Suyama T., Ueda T., Fukasawa S., Imamura Y., Nakamura K., Miyasaka K., Sazuka T., Egoshi K., Nihei N., Hamano M., Ichikawa T, Maruoka M. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn. J. Clin. Oncol. 2009;39:244.
  22. Kanai K., Kikuchi E., Ohigashi T., Miyajima A., Nakagawa K., Nakashima J., Oya M. Gemcitabine and paclitaxel chemotherapy for advanced uro thelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int. J. Clin. Oncol. 2008;13:510.
  23. Albers P., Park S.I., Niegisch G., Fechner G., Steiner U, Lehmann J., Heimbach D., Heidenreich A., Fimmers R., Siener R.; AUO Bladder Cancer Group. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol. 2011;22:288.
  24. Kouno T., Ando M., Yonemori K., Matsumoto K., Shimizu C., Katsumata N., Komiyama M., Okajima E., Matsuoka N., Fujimoto H., Fujiwara Y. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur. Urol. 2007;52:1115.
  25. Edeline J., Loriot Y., Culine S., Massard C., Albiges L., Blesius A., Escudier B., Fizazi K. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur. J. Cancer. 2012;48:1141.
  26. Lee J.H., Kang S.G., Kim S.T., Kang S.H., Choi I.K., Park Y.J., Oh S.C., Sung D.J., Seo J.H., Cheon J., Shin S.W., Kim Y.H., Kim J.S., Park K.H. Modified MVAC as a second-line treatment for patients with metastatic urothelial carcinoma after failure of gemcitabine and cisplatin treatment. Cancer Res. Treat. 2014;46:172.
  27. Powles T., EderJ.P., Fine G. D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S., Chen D.S., Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558.
  28. Plimack E.R., Gupta S., Bellmunt J., Berger R., Montgomery B., Gonzalez E.J., Pulini J., Dolled-Filhart M., Emancipator K., Pathiraja K., Gause C., Perini R., Cheng J., O'Donnell P.H. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. Ann. Oncol. 2014;(Suppl. 25):abstract LBA23.
  29. Culine S., Theodore C., De Santis M., Bui B., Demkow T., Lorenz J., Rolland F., Delgado F.M., Longerey B., James N. A phase II study of vin-flunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer. 2006;94:1395.
  30. Vaughn D.J., Srinivas S., Stadler W.M., Pili R., Petrylak D., Sternberg C.N., Smith D.C., Ringuette S., de Wit E., Pautret V., George C. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009;115:4110.
  31. Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., Delgado F.M., Hurteloup P., Winquist E., Morsli N., Salhi Y., Culine S., von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009;27:4454.
  32. Bellmunt J., Fougeray R., Rosenberg J.E., von der Maase H., Schutz F.A., Salhi Y., Culine S., Choueiri T.K. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol. 2013;24:1466.
  33. Castellano D., Puente J., de VelascoG., Chirivella I., Lopez-Criado P., Mohedano N., Fernandez O., Garcia-Carbonero I., Gonzalez M.B., Grande E. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14(779).
  34. Retz M., de Geeter P., Goebell P.J., Matz U., de Schultz W., Hegele A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC. Cancer. 2015;15(455).
  35. Medioni J., Di Palma M., Guillot A., Spaeth D., Theodore C. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC. Cancer. 2016;16(1):217.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies